首页> 外文期刊>Journal of the Chinese Medical Association: JCMA >Long-term results of stenting versus coronary artery bypass surgery for left main coronary artery disease—A single-center experience
【24h】

Long-term results of stenting versus coronary artery bypass surgery for left main coronary artery disease—A single-center experience

机译:支架置入术与冠状动脉搭桥术治疗左主干冠状动脉疾病的长期结果-单中心经验

获取原文
获取外文期刊封面目录资料

摘要

Background: Percutaneous coronary intervention (PCI) has emerged as an alternative treatment to coronary artery bypass grafting (CABG) for unprotected left main (LM) coronary artery disease, but the results of both treatments are less clear in real-world practice. We aimed to assess the long-term outcomes of unprotected LM disease treated with CABG or PCI with stenting in high-risk population from a single center. Methods: We collected 478 consecutive patients with unprotected LM disease (PCI/CABG: 208/270; mean age: 70?±?11?years; 85% male), and 252 patients were considered to be at high risk (European System for Cardiac Operative Risk Evaluation ≥6). The median follow-up was 4.3?years (interquartile range: 2.7–6.5?years). Results: All-cause death (PCI/CABG: 27.4%/31.5%; p?=?0.36) and all-cause death/myocardial infarction (MI)/stroke (PCI/CABG: 30.8%/35.9%; p?=?0.49) were comparable between the two groups, whereas the repeat revascularization rate was significantly higher in the PCI group (PCI/CABG: 22.6%/11.0%; p?
机译:背景:经皮冠状动脉介入治疗(PCI)已成为冠状动脉旁路移植术(CABG)的另一种治疗方法,用于无保护的左主干(LM)冠状动脉疾病,但在现实世界中,这两种治疗方法的结果尚不清楚。我们旨在评估从单个中心对高危人群进行CABG或PCI支架置入治疗的无保护的LM疾病的长期结果。方法:我们收集了478例连续性无保护性LM疾病的患者(PCI / CABG:208/270;平均年龄:70?±?11?岁; 85%的男性),其中252例被认为是高危患者(欧洲系统心脏手术风险评估≥6)。中位随访时间为4。3年(四分位间距:2。7-6。5年)。结果:全因死亡(PCI / CABG:27.4%/ 31.5%; p = 0.36)和全因死亡/心肌梗塞(MI)/中风(PCI / CABG:30.8%/ 35.9%; p =两组之间的比较[0.49]相当,而PCI组的重复血运重建率明显更高(PCI / CABG:22.6%/ 11.0%; p <0.01)。用倾向得分调整后,这些结果仍然相似。值得注意的是,CABG往往与较高的围手术期死亡率(校正后的p = 0.08)和长期卒中(校正后的p = 0.05)相关,而PCI与较高的长期MI相关(校正后的p = 0.09)。 )。糖尿病亚组(PCI / CABG:98/124)的分析得出了相似的结果。结论:就全因死亡/心梗/卒中的长期风险而言,对于无保护的LM疾病的高危患者,PCI可以替代CABG,但重复血运重建率明显更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号